The Multiple Myeloma Research Foundation Inc

SEE SCHEDULE O

THE MMRC IS A NETWORK OF 14 LEADING CANCER CENTERS AND ADDRESSES THREE CRITICAL AREAS OF UNMET NEEDS: HIGH-RISK SMOLDERING MYELOMA, HIGH-RISK UPFRONT TREATMENT FOR SYMPTOMATIC MULTIPLE MYELOMA, AND RELAPSED/REFRACTORY TREATMENT AFTER ANTI-CD38 AND BCMA-DIRECTED THERAPIES.IN 2023, THE MMRF DEVELOPED THE HORIZON ADAPTIVE TRIALS PROGRAM. SLATED TO OPEN IN 2024, HORIZON WILL TEST TREATMENT STRATEGIES THROUGH TWO TRIALS IN PATIENTS WITH RELAPSED/REFRACTORY DISEASE AND THOSE WHO ARE NEWLY DIAGNOSED AND HAVE HIGH-RISK DISEASE. THE ADAPTIVE NATURE OF THE TRIALS ALLOWS INVESTIGATORS TO TEST MULTIPLE THERAPIES SIMULTANEOUSLY AND REDUCE THE AMOUNT OF TIME NEEDED TO EVALUATE NEW THERAPIES. INVESTIGATORS CAN THEN RAPIDLY EXPAND PATIENT COHORTS RECEIVING TREATMENT REGIMENS WITH POSITIVE OUTCOMES AND EFFICIENTLY CLOSE EXPERIMENTAL PROTOCOLS WITH LESS-THAN-OPTIMAL OUTCOMES. GROUNDBREAKING CLINICAL TRIALS LIKE HORIZON ARE ONLY POSSIBLE THROUGH LARGER-SCALE, MULTI-INSTITUTIONAL COOPERATION. THESE TRIALS ALLOW THE MMRC TO EXPLORE COMBINATION THERAPIES REGARDLESS OF MANUFACTURER, PUTTING THE MOST PROMISING SCIENCE AND THE URGENT NEED OF PATIENTS AHEAD OF PHARMACEUTICAL PROFITS OR INDUSTRY COMPETITION.

IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. AS A PATIENT-FOUNDED ORGANIZATION, THE MMRF STANDS TOGETHER WITH THOSE WHO ARE BATTLING MULTIPLE MYELOMA - PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF STANDS APART WITH ITS INNOVATIVE APPROACH. THE MMRF GENERATES, INTERPRETS, AND ACTIVATES THE LARGEST COLLECTION OF HIGH-QUALITY DATA AND PLACES IT IN THE PUBLIC DOMAIN. THE MMRF ORCHESTRATES THE PEOPLE, PROGRAMS, AND TECHNOLOGIES NECESSARY TO SPEED THE DISCOVERY OF A CURE FOR EACH AND EVERY PATIENT.

IN 2023, THE MMRF CONTINUED TO BUILD OUT THE MMRF IMMUNE ATLAS INITIATIVE (THE "ATLAS"), AN IMMUNE PROFILING AND ANALYTICS PLATFORM USING DATA AND SAMPLES FROM THE COMMPASS STUDY TO GENERATE DATA ON THE ROLE OF PATIENT IMMUNITY IN MYELOMA DISEASE BIOLOGY AND RESPONSE TO THERAPY, AND TO SUPPORT AND SPEED EFFORTS TO MAKE IMMUNOTHERAPY MORE PRECISE FOR MYELOMA PATIENTS. THE ATLAS WILL DESCRIBE THE IMMUNE LANDSCAPE IN MYELOMA AND HOW IT CHANGES THROUGHOUT THE COURSE OF THE DISEASE AND TREATMENT. THIS EFFORT IS A CRITICAL FIRST STEP TO ESTABLISH GUIDELINES AND ALIGNMENT ON HOW IMMUNE DATA IS PRODUCED, PRIORITIZED, AGGREGATED, AND SHARED. AT SCALE, IT HAS THE POTENTIAL TO IDENTIFY NEW IMMUNOLOGIC FACTORS PREDICTIVE OF PATIENT RESPONSE OR RELAPSE TO THERAPY, TO IDENTIFY NEW IMMUNE TARGETS FOR DRUG DEVELOPMENT AND, EVENTUALLY, ENABLE CLINICIANS TO CUSTOMIZE TREATMENTS AND THERAPIES BASED ON AN INDIVIDUAL'S IMMUNE SYSTEM.

IN 2023, THE MMRF CONCLUDED ENROLLMENT IN THE MMRF CURECLOUD ("CURECLOUD") RESEARCH INITIATIVE, MAKING IT ONE OF THE LARGEST LONGITUDINAL DATA SETS IN MULTIPLE MYELOMA, WITH OVER 1,000 PATIENTS ENROLLED. THE DATA FROM THIS STUDY, WHICH INCLUDES CLINICAL GENOMIC, IMMUNE, AND PATIENT-REPORTED OUTCOMES, IS BEING ANALYZED IN ONGOING RESEARCH AND WILL BE MADE AVAILABLE TO RESEARCHERS TO HELP ANSWER IMPORTANT MYELOMA RESEARCH QUESTIONS AND INFORM FUTURE MMRF DATA-GENERATING INITIATIVES, ALL IN SUPPORT OF THE MMRF'S MISSION.